Publicaciones en colaboración con investigadores/as de Medical University of Vienna (27)

2024

  1. Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry

    Journal of Cardiac Failure

  2. Molecular states associated with dysfunction and graft loss in heart transplants

    Journal of Heart and Lung Transplantation, Vol. 43, Núm. 3, pp. 508-518

  3. Redefining the molecular rejection states in 3230 heart transplant biopsies: Relationships to parenchymal injury and graft survival

    American Journal of Transplantation, Vol. 24, Núm. 8, pp. 1414-1426

2023

  1. Donor heart selection: Evidence-based guidelines for providers

    Journal of Heart and Lung Transplantation, Vol. 42, Núm. 1, pp. 7-29

  2. SERCA2a Protein Levels Are Unaltered in Human Heart Failure

    Circulation, Vol. 148, Núm. 7, pp. 613-616

  3. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

  4. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial

    JACC: Heart Failure, Vol. 11, Núm. 12, pp. 1729-1738

2022

  1. Assessing the Relationship Between Molecular Rejection and Parenchymal Injury in Heart Transplant Biopsies

    Transplantation, Vol. 106, Núm. 11, pp. 2205-2216

  2. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  3. Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies

    European heart journal, Vol. 43, Núm. 23, pp. 2237-2246

  4. Indications, Complications, and Outcomes of Cardiac Surgery After Heart Transplantation: Results From the Cash Study

    Frontiers in Cardiovascular Medicine, Vol. 10

  5. Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes

    Journal of Heart and Lung Transplantation, Vol. 41, Núm. 3, pp. 334-344

2021

  1. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

    New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116

  2. Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 6, pp. 1311-1319

2020

  1. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

    European Journal of Heart Failure, Vol. 22, Núm. 11, pp. 2160-2171

2019

  1. 2018 update of the EULAR recommendations for the management of hand osteoarthritis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 1, pp. 16-24

  2. 2019 EACTS Expert Consensus on long-term mechanical circulatory support

    European Journal of Cardio-thoracic Surgery, Vol. 56, Núm. 2, pp. 230-270

  3. An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms

    Journal of Heart and Lung Transplantation, Vol. 38, Núm. 6, pp. 636-646

2018

  1. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 20, Núm. 11, pp. 1505-1535

  2. Exploring the cardiac response to injury in heart transplant biopsies

    JCI insight, Vol. 3, Núm. 20